Daniel Y. Song, MD, presented “Industry Perspective: BioProtect Balloon Implant™ System” at the 34th Annual International Prostate Cancer Update in Vail, Colorado, on February 12, 2024.
How to cite: Song, Daniel Y. “Industry Perspective: BioProtect Balloon Implant™ System.Industry Perspective: BioProtect Balloon Implant™ System.” February 12, 2024. Accessed Jul 2024. https://grandroundsinurology.com/industry-perspective-bioprotect-balloon-implant-system
Industry Perspective: BioProtect Balloon Implant™ System – Summary
In this Industry Perspective, supported by BioProtect, Daniel Y. Song, MD, compares the BioProtect Balloon Implant™ System to rectal gel spacers currently on the market. Dr. Song begins by presenting the composition, dimensions, and safety features of the balloon.
Dr. Song then compares the balloon’s features and implantation process to those of the two most readily available rectal gel spacers on the market. He notes that, unlike the gel spacers, the balloon creates predictable, reproducible, symmetrical results.
Dr. Song presents a step-by-step illustration of the implantation process for the BioProtect Balloon Implant™ System. He presents a video demonstration of an implantation procedure via blunt dissection, which reduces the risk of rectal, capsular, and vascular infiltration. He adds that the balloon is simple to degrade, with 98% of the material degraded at the 6-month mark.
Dr. Song concludes by presenting the results of the BioProtect Multinational Pivotal Study. He compares the 3- and 6-month GI toxicities of patients treated with rectal gel spacers versus those treated with the BioProtect Balloon Implant™ System. He demonstrates that the balloon achieves robust reduction in radiation dose, while being well-tolerated by patients and easy for healthcare professionals to implant and adjust.
ABOUT THE AUTHOR
Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer.
Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy.
Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium.
